SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - April 02, 2008) - Novogen today announced the commencement of a Phase I human clinical trial of the novel cardiovascular drug, NV-27. This drug is designed to reduce restenosis or re-blocking of arteries after surgery to clear blockages, commonly involving insertion of arterial stents. The study is being conducted in association with Bond University, Queensland, Australia under the direction of clinical pharmacologist, Professor Laurie Howes.
